GACM
TCRT icon

Green Arrow Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Green Arrow Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,167
Closed -$690K – 317
2013
Q3 		$690K Buy
+1,167
New +$526K 0.05% 231

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Green Arrow Capital Management's TCRT Position: Q4 2013 in Review

Green Arrow Capital Management sold out of Alaunos Therapeutics (TCRT) in Q4 2013, closing a stake of 1,167 shares — an estimated $690K sold.

Green Arrow Capital Management first reported a position in TCRT in Q3 2013 and held it in 1 quarter. The position peaked at $690K in Q3 2013. 78 funds tracked by Wall St. Rank hold TCRT as of Q4 2013.

  • Green Arrow Capital Management reported no remaining Alaunos Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Green Arrow Capital Management sold 1,167 Alaunos Therapeutics shares in Q4 2013, an estimated $690K.
  • Green Arrow Capital Management first reported a position in Alaunos Therapeutics in Q3 2013 and held it in 1 quarter.
  • Green Arrow Capital Management's Alaunos Therapeutics position peaked at $690K in Q3 2013.
  • 78 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2013.

Based on Green Arrow Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.